A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson’s disease.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
GLP-1 drug fails to slow Parkinson's: Study
